Case report and literature review: histologic transformation from EGFR-mutant lung adenocarcinoma to squamous cell carcinoma with newly detected SMAD4 and ATM variants
4 affiliations
- 1Department of Integrative Oncology, China-Japan Friendship Hospital
- 2Deaprtment of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
- 3Department of Pathology, China-Japan Friendship Hospital
- 4Department of Oncology, Beijing Chaoyang District Hospital of Traditional Chinese Medicine
Abstract
Background: Adenocarcinoma-to-squamous cell carcinoma transdifferentiation (AST) is an uncommon but clinically important form of histologic evolution in EGFR-mutant lung adenocarcinoma. Its underlying molecular mechanisms remain incompletely understood. Longitudinal genomic profiling may help characterize molecular alterations accompanying lineage transdifferentiation.
Case presentation: A 60-year-old woman with lung adenocarcinoma previously underwent surgical resection, and molecular testing identified an EGFR exon 19 deletion (EGFR 19del). After multiple lines of EGFR tyrosine kinase inhibitors and systemic therapy, she developed pleural recurrence. Repeat biopsy revealed a squamous phenotype, with positive p40 and CK5/6 staining and loss of TTF-1 and Napsin A expression, supporting AST. Longitudinal next-generation sequencing (NGS) showed that EGFR 19del and a TP53 p.R175H mutation were present both at baseline and after transformation, whereas SMAD4 p.D351V and ATM p.E1139K variants were newly detected only in the post-transformation tumor. After transformation, the patient received carboplatin, nab-paclitaxel, and tislelizumab and achieved a partial response.
Conclusion: We report a case of AST after multiple lines of therapy in a patient with EGFR-mutant lung adenocarcinoma and summarize potential molecular mechanisms and treatment developments in AST. Longitudinal NGS identified SMAD4 p.D351V and ATM p.E1139K variants in the post-transformation tumor. Functional evidence suggests that SMAD4 p.D351V may impair SMAD4-dependent BMP/TGF-β signaling, whereas the functional significance of ATM p.E1139K remains unclear. Further studies are needed to determine whether either variant contributes to AST.
Related
- Case Report: Sacrococcygeal teratoma with malignant transformation into mixed adenocarcinoma and squamous cell carcinoma following TNF-α inhibitor therapy for ankylosing spondylitis
- Synchronous laryngeal squamous cell carcinoma and papillary urothelial carcinoma of the bladder: a case report and literature review
- Squamous cell carcinoma in situ and syringocystadenocarcinoma papilliferum overlap in an Asian patient: A case report and review of the literature
- Transformation to Small‐Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR‐Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report
- Regulatory network remodeling and potential non-canonical associations of the transcription factor SP1 during inflammation-to-cancer transformation in esophageal squamous cell carcinoma
BibTeX
@article{wang2026case,
title = {{Case report and literature review: histologic transformation from EGFR-mutant lung adenocarcinoma to squamous cell carcinoma with newly detected SMAD4 and ATM variants}},
author = {Chao Wang and Shuo Wang and Daixi Wu and Yanni Lou and HongYan Liu and Yu Tang and Fei Su and Liqun Jia},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1982968},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1982968/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case report and literature review: histologic transformation from EGFR-mutant lung adenocarcinoma to squamous cell carcinoma with newly detected SMAD4 and ATM variants
AU - Chao Wang
AU - Shuo Wang
AU - Daixi Wu
AU - Yanni Lou
AU - HongYan Liu
AU - Yu Tang
AU - Fei Su
AU - Liqun Jia
PY - 2026
DA - 2026/10/27
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1982968
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1982968/full
AB - Background: Adenocarcinoma-to-squamous cell carcinoma transdifferentiation (AST) is an uncommon but clinically important form of histologic evolution in EGFR-mutant lung adenocarcinoma. Its underlying molecular mechanisms remain incompletely understood. Longitudinal genomic profiling may help characterize molecular alterations accompanying lineage transdifferentiation. Case presentation: A 60-year-old woman with lung adenocarcinoma previously underwent surgical resection, and molecular testing identified an EGFR exon 19 deletion (EGFR 19del). After multiple lines of EGFR tyrosine kinase inhibitors and systemic therapy, she developed pleural recurrence. Repeat biopsy revealed a squamous phenotype, with positive p40 and CK5/6 staining and loss of TTF-1 and Napsin A expression, supporting AST. Longitudinal next-generation sequencing (NGS) showed that EGFR 19del and a TP53 p.R175H mutation were present both at baseline and after transformation, whereas SMAD4 p.D351V and ATM p.E1139K variants were newly detected only in the post-transformation tumor. After transformation, the patient received carboplatin, nab-paclitaxel, and tislelizumab and achieved a partial response. Conclusion: We report a case of AST after multiple lines of therapy in a patient with EGFR-mutant lung adenocarcinoma and summarize potential molecular mechanisms and treatment developments in AST. Longitudinal NGS identified SMAD4 p.D351V and ATM p.E1139K variants in the post-transformation tumor. Functional evidence suggests that SMAD4 p.D351V may impair SMAD4-dependent BMP/TGF-β signaling, whereas the functional significance of ATM p.E1139K remains unclear. Further studies are needed to determine whether either variant contributes to AST.
SN - 2234-943X
ER -